Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer, Medivation Sign Alzheimer's Pact

September 8, 2008 | A version of this story appeared in Volume 86, Issue 36

Pfizer has signed an agreement with Medivation, a San Francisco biopharmaceutical firm focused on small molecules, to codevelop and comarket dimebon, a drug for the treatment of Alzheimer's and Huntington's diseases. Under the agreement, Medivation will receive an up-front payment of $225 million, will be eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones, and could reap undisclosed commercial milestone payments. Dimebon is currently in Phase III clinical trials for Alzheimer's disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.